Medical drug program updates
You can refer to the chart below to review changes and updates related to CarePartners of Connecticut's prior authorization and coverage program for medical drugs.
New prior authorization programs | ||
Drug/MNG | Additional information | Effective date |
CarePartners of Connecticut will cover Zevaskyn (J3389), an autologous cell sheet-based gene therapy indicated for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa, with prior authorization when the criteria on the MNG (which align with MassHealth’s criteria) have been met. | 4/1/2026 | |